Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Report, H1 2017 - Review of 14 Companies and Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 13 and 1 respectively.

Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Paroxysmal Nocturnal Hemoglobinuria - Overview
  4. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
  • Achillion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • ISU ABXIS Co Ltd
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Omeros Corp
  • Ra Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Regenesance BV

For more information about this report visit http://www.researchandmarkets.com/research/zn5bm5/paroxysmal

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs